Skyepharma has announced that Mundipharma has launched the Flutiform fluticasone/formoterol MDI for the treatment of asthma in Spain, triggering a milestone payment of €2.0 million. In addition, Mundipharma marketing partner Zambon Italia has now launched the same product in Italy under the brand name Abriff. Mundipharma Italy has been marketing the inhaler as Flutiformo in Italy since June 2013.
In Japan, Kyorin has launched 120 inhalation versions of Flutiform 50µg/5µg and Flutiform 125µg/5µg inhalers. Kyorin has marketed 56-inhalation versions of the MDI in Japan since November 2013 in accordance with rules set out by Japanese National Health Insurance.
Skyepharma CEO Peter Grant said, “Flutiform is now available in the five largest European markets and represents a new treatment option for clinicians and asthma patients in Spain. With this latest launch in a key market and an enhanced distribution network in Italy, we look forward to continued progress.”
Kyorin Pharmaceutical President Mitsutomo Miyashita commented, “Now that the limitation for prescription duration has been lifted, we are launching the 120-puff version of flutiform for 30-day supplies. We strongly believe that the launch of the new version of flutiform will encourage the rapid penetration of the drug into the Japanese market and greatly contribute to taking control of asthma in patients.”
Read the Skyepharma press release on the launch in Spain.
Read the Skyepharma press release on the launch in Japan.
Read the Kyorin press release.
